Abcema Clinical Trial Results:
- Overall response rate: 94%
- Complete response rate: 40%
- Duration of response: 10.6 months
- Progression-free survival: 8.6 months
- Adverse effects: cytokine release syndrome, infections, fatigue, musculoskeletal pain, and hypogammaglobulinemia.
- Further information on adverse effects can be found on the drug label, which has a black box warning and a Risk Evaluation and Mitigation Strategy (REMS).
SOURCE: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4697-abcema-idecabtagene-vicleucel